June is Men’s Health Month, a national observance that aims to raise awareness of healthcare for men, such as a higher risk of heart disease, cancer or sexually transmitted diseases.
Eli Lilly is currently the sponsor with the most men’s health clinical trials, with 90 trials; Bayer is second with 85, followed by GlaxoSmithKline (GSK) with 60. The top ten sponsors can be seen in Figure 1, which also shows that the majority of Eli Lilly’s trials are completed. When looking at ongoing trials in men’s health, these are heavily sponsored by institutions.
At present, nine of the top ten sponsors for ongoing men’s health clinical trials are institutions, with the exception of Health Decisions, which is fifth (Figure 2). Massachusetts General Hospital currently has the most ongoing trials, with nine. It has five Phase I trials, three Phase II, and only one in Phase III. The most common indication for these nine trials is male hypogonadism, a condition where the body does not produce enough testosterone hormones.
MGH’s most recent trial is ‘Opioid Antagonism in Hypogonadotropic Hypogonadism’, which started on 31 March. The purpose of this study is to evaluate the effects of opioid antagonists (Kisspeptin-10, naloxone, gonadotropin-releasing hormone) on the hypothalamic-pituitary-gonadal axis in subjects with idiopathic hypogonadotropic hypogonadism. The trial looks to enrol 23 subjects and hopes to be completed on 30 November 2024.